for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi and GSK launch trial for COVID-19 protein-based vaccine

PARIS, Sept 3 (Reuters) - French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments against the coronavirus pandemic.

Sanofi and GSK said in a joint statement on Thursday they had started the “Phase 1/2” trial for their adjuvanted COVID-19 vaccine, which they hope to make available across the world.

This vaccine candidate uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology. (Reporting by Sudip Kar-Gupta; Editing by Tom Hogue)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up